84C Stock Overview
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Clene Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.37 |
52 Week High | US$1.10 |
52 Week Low | US$0.23 |
Beta | 0.48 |
1 Month Change | -2.62% |
3 Month Change | 32.86% |
1 Year Change | -62.80% |
3 Year Change | -96.82% |
5 Year Change | n/a |
Change since IPO | -94.35% |
Recent News & Updates
Recent updates
Shareholder Returns
84C | DE Biotechs | DE Market | |
---|---|---|---|
7D | 6.3% | 2.1% | 1.9% |
1Y | -62.8% | 37.0% | 7.3% |
Return vs Industry: 84C underperformed the German Biotechs industry which returned 37% over the past year.
Return vs Market: 84C underperformed the German Market which returned 7.3% over the past year.
Price Volatility
84C volatility | |
---|---|
84C Average Weekly Movement | 16.8% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 84C's share price has been volatile over the past 3 months.
Volatility Over Time: 84C's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 84 | Rob Etherington | https://clene.com |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.
Clene Inc. Fundamentals Summary
84C fundamental statistics | |
---|---|
Market cap | €50.33m |
Earnings (TTM) | -€45.75m |
Revenue (TTM) | €604.36k |
83.3x
P/S Ratio-1.1x
P/E RatioIs 84C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
84C income statement (TTM) | |
---|---|
Revenue | US$654.00k |
Cost of Revenue | US$121.00k |
Gross Profit | US$533.00k |
Other Expenses | US$50.04m |
Earnings | -US$49.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.39 |
Gross Margin | 81.50% |
Net Profit Margin | -7,569.42% |
Debt/Equity Ratio | 199.1% |
How did 84C perform over the long term?
See historical performance and comparison